Compass Therapeutics to Participate in Upcoming May Investor Events
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Compass Therapeutics (NASDAQ: CMPX), a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapeutics, has announced its participation in two major investor events in May 2025. The company will present at The Citizens Life Sciences Conference in New York on May 8, 2025, at 1:30 PM ET, and at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on May 20, 2025, at 11:30 AM ET. Both presentations will be available via webcast and archived for 90 days on Compass' Events page.
Details
News Market Reaction – CMPX
The recorded move for CMPX in the trading session of this news was -9.14%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month of May.
Details are as follows:
The Citizens Life Sciences Conference
Location: New York, NY
Date: Thursday, May 8, 2025
Time: 1:30 PM ET
Webcast Link: https://wsw.com/webcast/jmp65/cmpx/1692592
H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
Location: New York, NY
Date: Tuesday, May 20, 2025
Time: 11:30AM ET
Webcast Link: https://journey.ct.events/view/29729b86-5109-46dc-a93b-1cf3560aa9a1
Virtual/Replay availability: Presentations will be archived for 90 days on Compass’ Events page.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Investor Contact
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Chief of Staff
media@compasstherapeutics.com
617-500-8099
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.